Brinker Capital Investments, LLC Apellis Pharmaceuticals, Inc. Transaction History

Brinker Capital Investments, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Jul 31, 2025	SELL	$28.84 - $41.15 $141,719 - $202,211	-4,914 Reduced 13.53%	31,418 $906,000
Q2 2024 Jul 31, 2025	BUY	$38.07 - $59.71 $352,261 - $552,496	9,253 Added 34.17%	36,332 $1.39 Million
Q1 2024 Jul 31, 2025	BUY	$55.39 - $72.47 $406,008 - $531,205	7,330 Added 37.12%	27,079 $1.59 Million
Q4 2023 Jul 31, 2025	SELL	$37.14 - $64.82 $284,009 - $495,678	-7,647 Reduced 27.91%	19,749 $1.18 Million
Q3 2023 Jul 31, 2025	BUY	$23.65 - $89.22 $253,362 - $955,813	10,713 Added 64.22%	27,396 $1.04 Million
Q2 2023 Jul 31, 2025	SELL	$76.68 - $93.31 $49,228 - $59,905	-642 Reduced 3.71%	16,683 $1.52 Million
Q1 2023 Jul 31, 2025	BUY	$46.59 - $66.96 $807,171 - $1.16 Million	17,325 New	17,325 $1.14 Million

305

134M

2.97M

623K

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.25B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Brinker Capital Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Brinker Capital Investments, LLC with notifications on news.